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Aaron’s attention to detail was as legendary as his focus 
on global thoughts. At that most recent holiday party he 
expressed his pleasure that we had continued his tradition 
of the huge shrimp bowl that had been the congregational 
centerpiece of his own parties. He recognized that the rock 
music and size of the event were relatively trivial departures 
from the past. He was obviously pleased that, despite stylis-
tic difference, the spirit and substance so important to him 
had not changed one iota.
Aaron embraced, and was a closely collaborating agent 
of, ongoing departmental evolution. He continually updat-
ed his own list of all faculty members, in both our own and 
other departments of dermatology, who had emanated from 
our training programs and followed their careers closely. 
He was consulted regularly and contributed substantially 
to the modifications we made in the postdoctoral training 
grant that he had originally achieved. This is just one of the 
numerous examples of how so many of our recent successes 
can be traced directly to his advice.
Well before the term was in vogue, Aaron was a pioneering 
“translational scientist.” Many of his scientific contributions 
have had lasting major clinical applications. The stories of 
cryoglobulins, melanocyte-stimulating hormone, melatonin, 
and psoralens continue to expand into new vistas. He was 
one of the first to recognize that the clinical manifestations of 
malignant cells—his focus being on melanoma—commonly 
reflect the biologic features of the normal cells of origin. This 
was a major lesson from him that my own group has attempt-
ed to amplify in our studies of human T-cell lymphomas and 
that has now been extended to all categories of cancer. Once 
again, Aaron was a trailblazer, far ahead of the curve.
We at Yale will miss him deeply, on every personal and 
professional level. We, and our own successors, will always 
be so very indebted to him for his having given us the chance 
to stand on his shoulders in the house that Aaron built.
Richard Edelson
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Current Understanding and Future Implications of 
the Circadian Uses of Melatonin, a Neurohormone 
Discovered by Aaron B. Lerner
Melatonin is related to circadian rhythms as both a dependent 
and an independent variable. As a dependent variable, the 
dim light melatonin onset (DLMO)—the time when melato-
nin levels rise in the evening—is the most widely used mark-
er for the timing of endogenous circadian rhythms in human 
chronobiology research and will soon be used in the clinic 
as well. The time interval (in hours) between the DLMO and 
mid-sleep is the phase angle difference (PAD) between them. 
PAD is expected to become an important marker for inter-
nal circadian alignment/misalignment. A PAD study recently 
reported a substantial circadian component of winter depres-
sion (seasonal affective disorder, or SAD) and its treatment 
with circadian phase-resetting agents. Although appropri-
ately timed bright light is the treatment of choice for SAD, it 
can also be treated with low-dose melatonin, an independent 
variable optimally administered for most patients in the after-
noon/evening, in order for this chemical signal of nighttime 
darkness to cause a corrective phase advance. Induction of 
a therapeutic phase delay, for example, in the treatment of 
advanced sleep phase syndrome (ASPS), requires that mela-
tonin be administered in the morning. Melatonin is the treat-
ment of choice for totally blind people with free-running cir-
cadian rhythms (blind free-runners, or BFRs).
What if Aaron Lerner had lived in the days of Walter 
Cannon (Cannon, 1939), or even Claude Bernard (Bernard, 
1927), and led his team to discover melatonin decades 
before 1958 (Lerner et al., 1959)? There might have been 
fewer years between melatonin’s identification and the dis-
covery of its physiological role in circadian homeostasis. On 
the other hand, perhaps work that began in the decade or 
two following Dr. Lerner’s discovery (Daan and Pittendrigh, 
1976; DeCoursey, 1960) was also necessary. In any event, we 
can now discern the broad outlines of melatonin’s circadian 
properties. A more complete understanding of Dr. Lerner’s 
melatonin legacy may require some speculations based on 
what is known at the present time.
Other monographs in this volume and elsewhere will cover 
the events around Dr. Lerner’s discoveries, as well as proper-
ties of melatonin that do not relate to the circadian system 
of humans. A review of work by others in the circadian field 
was recently published (Wirz-Justice, 2006). Noncircadian 
properties generally depend on supraphysiological levels of 
melatonin. Therefore, some potentially therapeutic uses of 
this safe and nonabusable neurohormone will not be consid-
ered here.
Physiological levels of melatonin appear to be sufficient 
for causing circadian phase shifts, as well as for providing 
an ideal biological marker for the phase of the endogenous 
circadian pacemaker (Lewy et al., 1992, 1998, 2005). Studies 
of the circadian aspects of melatonin have resulted in thera-
peutic uses and advanced our understanding of melatonin 
physiology (Lewy et al., 2006b). Perhaps uniquely, administra-
tion of even high doses of melatonin does not cause negative 
feedback inhibition on the level of its production (Matsumoto 
et al., 1997). Therefore, in the original formulations of homeo-
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stasis, melatonin is an exception. The melatonin homeostat, 
however, may be found in its temporal organization.
Melatonin is produced in virtually all species almost 
entirely during nighttime darkness (Arendt, 1995). In verte-
brates, circulating levels of melatonin are derived from the 
pineal gland, which responds to interactions between the 
endogenous circadian pacemaker and the light–dark cycle 
(Lewy et al., 1980a; Neuwelt and Lewy, 1983). Exposure to 
light suppresses melatonin production (Lewy et al., 1980b). 
Most mammals use the duration of melatonin production as 
it corresponds to the annual change in scotoperiod to regu-
late seasonal rhythms (Arendt, 1995).
Although humans do not have seasonal rhythms to nearly 
the extent that other mammals do, light is the most impor-
tant time cue (zeitgeber) for the regulation of human circa-
dian rhythms. Furthermore, the suppressant effect of light has 
been retained in humans (Lewy et al., 1980b). Studies on the 
suppressant effect of light suggest that the circadian phase-
shifting effects of light are intensity dependent (Lewy et al., 
1980b). Thus, SAD is thought to occur because ordinary-
intensity indoor light is relatively less effective than brighter 
sunlight (Lewy et al., 1987a). Although several studies have 
pursued a seasonal, or photoperiodic, mechanism for SAD, 
most investigators now think that SAD has a circadian basis.
Morning light causes a phase advance (shift to an earlier 
time) in circadian rhythms; evening light causes a phase delay 
(shift to a later time) (Lewy et al., 1987a). Between these two 
daily phase shifts, stable entrainment to the 24-hour day 
requires a net shift that equals the difference between 24 
hours and a person’s circadian period (tau), which is slightly 
different from 24 hours. For example, if tau = 24.3 hours and 
evening light causes a phase delay of 0.4 hours, then a phase 
advance of 0.7 hours (0.3 + 0.4 hours) must result from morn-
ing light to prevent a person from free-running.
The phase shift hypothesis (PSH) for winter depression pos-
its that most patients with SAD become depressed at least 
in part due to the later winter dawn that results in a delay in 
circadian rhythms relative to the sleep–wake cycle (Lewy et 
al., 1987b). Supporting evidence for this hypothesis has come 
from measuring melatonin. It is now acknowledged that the 
DLMO is the best marker for circadian phase (Lewy et al., 
1999; Lewy and Sack, 1989). The DLMO developed from the 
finding that bright light can suppress melatonin production in 
humans (Lewy et al., 1980b). Hence, in sighted people, sali-
va (Burgess et al., 2003; Lewy et al., 2006b; Vakkuri, 1985) 
or blood samples are collected under dim light; the current 
recommendation is less than 30 lux. One of the advantages 
of the DLMO is that frequent sampling (every 30 min) in the 
evening provides a phase marker of high resolution, and the 
sampling procedure usually does not need to extend beyond 
a person’s usual bedtime. Last year, Dr. Lerner performed a 
salivary DLMO in his own home. His DLMO, as defined by 
the time when levels continuously rose above 3 pg/ml, was 
shortly after 6:30 p.m., a sign of ASPS, which is common in 
the elderly.
A recent test of the PSH in SAD was communicated to the 
Proceedings of the National Academy of Sciences (PNAS) by 
Dr. Lerner (Lewy et al., 2006c). This study was perhaps the 
first time in which symptom severity in a psychiatric disorder 
was shown to correlate with a physiological marker before 
and in the course of treatment in the same patients. The 
physiological marker was the PAD between the DLMO and 
mid-sleep. The average PAD in healthy controls is 6 hours, 
which turns out to be the PAD for optimal mood in SAD, 
as well as for phase typing patients: individuals with PAD 
<6 hours are phase typed as delayed and individuals with PAD 
>6 hours are phase typed as advanced. Bright light scheduled 
in the morning provides a corrective phase advance, which 
is therapeutic in the prototypical phase-delayed SAD patient; 
bright light scheduled in the evening provides a phase delay 
that should be therapeutic in the minority of SAD patients 
who are phase advanced (Lewy et al., 1987a). In the PNAS 
study (Lewy et al., 2006c), low-dose (<0.3 mg) melatonin 
was used to cause therapeutic phase shifts: according to the 
melatonin phase response curve, melatonin administered in 
the afternoon/evening caused phase advances and melatonin 
administered in the morning caused phase delays (Lewy et 
al., 1992, 1998). Based on his DLMO test, Dr. Lerner took 
0.3 mg melatonin at wake time, which provided the desired 
phase delay in his circadian rhythms, allowing him to stay up 
later in the evening and sleep later in the morning.
The PNAS study (Lewy et al., 2006c) was undertaken to 
test the mechanism of action of bright light, the treatment of 
choice in SAD. Melatonin was used in this study to reduce 
the placebo response, which is known to be a considerable 
component of light treatment. Just as morning bright light is 
recommended for most SAD patients, we can now recom-
mend afternoon/evening melatonin for them. In this study, 
the therapeutic potential of melatonin was not optimized. 
Nevertheless, the benefit over placebo was comparable to 
the most robust findings published for antidepressant medi-
cations, and melatonin’s antidepressant onset of action is 
quicker. Although melatonin is not considered an antidepres-
sant per se, its ability to provide corrective phase shifts may 
eventually lead to its use in treating depression of different 
types, not just SAD. Because anxiety symptoms are also pres-
ent in depressed patients, melatonin prescribed to induce 
appropriate phase shifts may prove to be efficacious in other 
disorders as well, including anxiety, sleep, and substance 
abuse disorders. Light and melatonin continue to be tested 
in the treatment of advanced and delayed sleep phase syn-
drome, jet lag, and shift-work maladaptation.
Several what-ifs come to mind in the context of the PNAS 
paper communicated by Dr. Lerner (Lewy et al., 2006c). What 
if the PAD in seasonal depression applies to other psychiatric 
and sleep disorders? PAD might be related to, and even caus-
al of, a core cluster of symptoms related to depression, anx-
iety, and insomnia that cuts across a number of Diagnostic 
and Statistical Manual of Mental Disorders diagnoses. PAD 
would not necessarily be a way of diagnosing these disor-
ders, which would still be done clinically. However, PAD 
might inform the practitioner about the likelihood that phase-
resetting agents, such as bright light and melatonin, will be of 
therapeutic benefit. PAD would also be used to indicate the 
appropriate direction for phase realignment and to monitor 
the course of therapy.
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What if the current treatments of these disorders acted 
in part by adjusting PAD? If PAD is a clinically meaningful 
component in these disorders, then future drug development 
may benefit from studies in which PAD is assessed before 
and in the course of treatment. Perhaps medications cur-
rently in use are therapeutic in part because of correcting 
circadian misalignment.
What if this first demonstration of a biological marker that 
correlates with symptom severity in a psychiatric disorder 
in the same patients, before and in the course of treatment, 
impacts the field of biological psychiatry by raising the bar 
for other putative biological markers? These criteria, which 
could be Koch’s postulates of psychiatry, might include the 
following:
1. The biological marker correlates with symptom severity 
before treatment.
2. The biological marker correlates with symptom severity 
in the course of treatment.
3. Symptom change scores correlate with the change in the 
biological marker.
The above would seem to be sufficient criteria for estab-
lishing a causal relationship between the biological marker 
and at least one component of the disorder. With regard to 
SAD, all the above criteria (and more) have been met. Prior 
to the PNAS study (Lewy et al., 2006c), the DLMO seemed to 
be useful at most for verifying what could already be deter-
mined by assessing sleep phase, for example, diagnosing 
people with ASPS. However, the PAD cannot be known with 
certainty from sleep clock time (Burgess et al., 2003). Both 
DLMO clock time and mid-sleep clock time must be ascer-
tained to assess circadian misalignment.
None of the above criteria requires demonstration of a 
difference in the biological marker between patients and 
healthy controls. The concept of an “ipsative” abnormality 
was introduced into this field in 1987 (Lewy et al., 1987b): 
an ipsative abnormality is one that is state dependent, in that 
the biological marker is abnormal when the patient is symp-
tomatic and normal when the patient is well. It is not yet 
known whether each person has his or her own normal PAD. 
In any event, a PAD not equal to 6 is not by itself diagnostic 
of any disorder.
In addition to the discovery of SAD and its treatment with 
bright light, as well as the development of the DLMO, anoth-
er result of the bright light suppression of melatonin finding 
(Lewy et al., 1980b) was stimulation of studies of circadian 
rhythms in another disorder related to even greater light 
deprivation. Total blindness occurs when individuals have 
no ability to detect light. The original report in 1983 (Lewy 
and Newsome, 1983) found evidence for three types of 
blind people: normally entrained, abnormally entrained, and 
free-running. In the same year, a landmark rodent study was 
published that demonstrated entrainment of free-running 
circadian rhythms to melatonin injections (Redman et al., 
1983). Within a decade, the first case report showing the suc-
cessful entrainment of a free-running blind person to melato-
nin appeared (Sack et al., 1990). In 2000 (Sack et al., 2000), 
the first statistically significant findings were published, on a 
group of seven BFRs.
Total blindness also provides an experiment of nature in 
which the circadian system of humans can be studied in the 
absence of any confounding effects of light. On the basis of 
these studies, it is now known that very low physiological 
doses can cause clinically significant circadian phase shifts 
(Lewy et al., 2002, 2005; Sack et al., 2000). Studies of blind 
adults have resulted in the finding that some of them are 
naturally entrained to unknown zeitgebers other than light 
through the eye (Emens et al., 2005; Lewy and Newsome, 
1983). Although most totally blind people are BFRs, all of 
them respond to these zeitgebers in the same way—although 
some are more responsive than others (Emens et al., 2005). 
Assuming these zeitgebers include social cues, the study of 
how BFRs are affected by these zeitgebers may lead to the 
identification of new circadian phase-resetting modalities, 
therapeutic for sighted people as well.
Based on studies in blind adults, melatonin can now be 
used in very young infants, including sighted infants, who 
normally are not able to entrain to the light–dark cycle until 
they are about 3 months old. Indeed, the function of endoge-
nous melatonin may be to entrain the third-trimester fetus and 
the “fourth-trimester” suckling infant to the mother’s sleep–
wake cycle through the mother’s melatonin transferred across 
the placenta or secreted in breast milk—provided she is not 
exposed to too much nighttime light (Lewy et al., 2006a).
In summary, we are just beginning to appreciate some of 
the implications of the discovery of melatonin by Aaron Lerner 
and his team. Melatonin may be the most important depen-
dent variable in the assessment of circadian sleep and psychi-
atric disorders. As an independent variable, it is the treatment 
of choice for blind people and may be a very important treat-
ment modality for sighted people as well. Even if not all of the 
what-ifs are realized, it is clear that Dr. Lerner’s melatonin leg-
acy is profound and significant for medicine and physiology.
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Aaron Lerner: Perspectives and Lessons Learned from the 
Melatonin Days
We talk much about translational research, sometimes in 
rather simple ways, even separating it from basic knowledge. 
Aaron Lerner created a perfect blend of basic and clinical 
science during a career that spanned more than 60 years. The 
discovery of melatonin was but one of his many important 
discoveries that impacted dermatology and neuroscience, 
part of his role as the leading contributor to the field of der-
matology of the past half century.
Becoming a scientist
By the time that Aaron Lerner started on the melatonin proj-
ect, he had the prepared mind that is so often key to great 
advances in science. He had, early on, a characteristic zest, 
curiosity, and capacity for creating scientific knowledge. 
While he was interested and able in many areas, Lerner’s 
commitment to science became intense when he started col-
lege. He received a BA cum laude in mathematics and chem-
istry, a medical degree, and a doctorate from the department 
of physiological and physical chemistry, all within seven years 
at the University of Minnesota. His research career began 
when he was a second-year undergraduate with investiga-
tions related to dopa, a critical tyrosine derivative involved in 
pigmentation. Before graduating from medical school, with 
another student and without an adviser, he was involved in 
the isolation of a globulin protein that is now recognized as 
the first isolation of a monoclonal antibody, cryoglobulin.
Through a series of scientific adventures and fortuitous 
interactions with preceptors and peers during a stint in the 
Army, Lerner became increasingly interested in issues of pig-
mentation, such as the processes by which tyrosine was con-
verted to melanin. At Case Western Reserve University, he 
obtained further superb postdoctoral training in biochemistry, 
studying processes involved in pigmentation. By the age of 
30, he had written a paper with his close colleague, Thomas 
Fitzpatrick, on melanin pigmentation for a leading publica-
tion, Physiological Reviews; this paper established them as 
among the world’s leading experts on the topic.
Pigmentation led to Aaron Lerner’s abiding interest in der-
matology and ultimately to a situation at the University of 
Michigan, where he could obtain residency training and also 
conduct research. Among many projects during that early 
phase, one of special import was investigating the pituitary 
factor that might be involved in the darkening of skin seen in 
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